Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 1;8(10):13279-83.
eCollection 2015.

ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer

Bo Ma  1 , Qianqian Ma  2 , Chunhui Jin  3 , Xiaohong Wang  4 , Guolei Zhang  4 , Huiying Zhang  4 , Harald Seeger  2 , Alfred O Mueck  2
Affiliations

ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer

Bo Ma et al. Int J Clin Exp Pathol. .

Abstract

Objectives: Our study was aimed to make sure whether ADAM12 could serve as a prognostic biomarker of estrogen receptor (ER) -positive breast cancer.

Methods: 127 patients with ER-positive breast cancer were included in the present study. The level of ADAM12 was assayed through real-time quantitative PCR (RT-qPCR). Levels of ADAM12 in tumor tissues and adjacent normal tissues were compared with paired t-test. The association of ADAM12 expression with clinical characteristics was analyzed via χ(2) test. Kaplan-Meier survival curve was used to evaluate the role of ADAM12 expression in overall survival (OS) of patients. Cox-regression analysis was performed to judge if ADAM12 could serve as a prognostic marker in breast cancer.

Results: The level of ADAM12 was upregulated in tumor tissues of breast cancer compared to that of adjacent normal tissues (P < 0.05). The expression of ADAM12 was closely related to the Ki-67 and HER2 status (P < 0.05 for both). The results of Kaplan-Meier survival curve showed that patients with higher level of ADAM12 exhibited shorter survival time compared to that of low level of ADAM12 (P < 0.001). Cox regression analysis showed that ADAM12 might be a biomarker in predicting prognosis of patients with ER-positive breast cancer (HR = 7.116, 95% CI = 3.329-15.212).

Conclusion: ADAM12 appears to be a prognostic marker in ER-positive breast cancer.

Keywords: ADAM12; breast cancer; clinical outcome; estrogen receptor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The expression level of ADAM12 in tumor tissues and adjacent normal tissues of ER-positive breast cancer. The level of ADAM12 in tumor tissues was significantly higher than that of normal tissues (P < 0.001). BC indicates breast cancer.
Figure 2
Figure 2
Kaplan-Meier survival curve. Increased expression of ADAM12 predicted worse clinical outcome of patients with ER-positive breast cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–1656. - PubMed
    1. Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging. 2013;57:312–321. - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
    1. Sorensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M, Larsen MJ, Kruse TA. Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers. Breast Cancer Res. 2015;17:55. - PMC - PubMed
    1. Tanaka M, Ichikawa-Tomikawa N, Shishito N, Nishiura K, Miura T, Hozumi A, Chiba H, Yoshida S, Ohtake T, Sugino T. Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion. BMC Cancer. 2015;15:53. - PMC - PubMed